CNTB stock news · Connect Biopharma Hldgs
Get alerts for CNTB
Follow Connect Biopharma Hldgs (CNTB) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CNTB12 health care stocks are changing in price during Wednesday's after-hours trading.
NeutralConnect Biopharma shares rose 6.4% after hours. The story gives no company update, so this move alone does not change its outlook.
Connect Biopharma says its new COPD treatment has 81% fewer failures than the old method.
Good for CNTBCNTB reported fewer treatment failures and flare-ups with its COPD drug in a Phase 2 study. The results support the company, though larger studies must confirm them.
12 health care companies are seeing big changes in their stock prices today.
NeutralConnect Biopharma shares rose 23% to $1.22. The article gives no company news explaining the move, so it does not change the business outlook.
12 health care companies are changing prices before the market opens on Wednesday.
NeutralThe report says CNTB shares rose 79.43%, but gives no company news or reason for the move. That does not show a change in its business outlook.
Connect Biopharma Holdings Ltd shares important news about its COPD treatment results.
Good for CNTBConnect Biopharma reported encouraging results for its COPD drug, including fewer treatment failures and flare-ups. The breathing-test result was not conclusive, but the overall news is positive for CNTB.
Connect Biopharma's stock dropped on Tuesday. What's going on?
NeutralConnect Biopharma had mixed Phase 2 results: primary missed, lung function improved and safety looked good. I read this as neutral for the company.
Connect Biopharma Holdings Ltd shared important news about its asthma treatment, rademikibart, showing good results in a study.
NeutralConnect Biopharma reported mixed Phase 2 asthma data: clear lung-function gain but missed the clinical primary endpoint, so the company's development path remains unchanged.